Ceva Joint-Venture with EBVAC Reinforces Position in China's Swine Market

CHINA - In the presence of the Chinese Prime Minister, Li Keqiang and French Prime Minister, Bernard Cazeneuve, Ceva Santé Animale (Ceva) and EBVAC have signed a joint-venture agreement to create a new business, Ceva EBVAC, focused on the swine sector.
calendar icon 22 February 2017
clock icon 4 minute read

China is by far the largest global producer of pork with half of the world’s pigs being raised in the country, underlining the importance of the new partnership for both companies.

EBVAC was founded in 2005 by China Animal Health and Epidemiology Center (CAHEC), through its subsidiary company Qingdao Yebio, a part of the National Institute of the Ministry of Agriculture. The company is based in Hangzhou City, near to Shanghai and focuses on vaccine research, production and service.

In 2016 it achieved sales of 140 million RMB (€19 million) and has averaged growth of 20 per cent pa for the past 5 years. Swine vaccines are the major driver of this growth, representing more than 55 per cent of sales.

The company is recognised as a National High-Tech Enterprise and has a broad network of scientific partnerships with local research institutes and universities and an international R&D joint-venture with the University of Cambridge, UK, CAMBIVAC.

Ceva is a French-based multinational biopharmaceutical group, the world’s 6th largest, with a balanced offering of vaccines and pharmaceutical products for swine producers.

Ceva will hold the majority of shares in the new partnership and through the addition of its own products to the EBVAC portfolio of vaccines, aims to create an innovative, market leading company.

Ceva has been present in China for 15 years and since 2011 has entered into a number of partnerships (joint-venture Ceva Huadu, scientific cooperation agreement with South China Agricultural University (SCAU), training programme for producers and veterinarians with the University of Beijing) designed to share knowledge and ensure that the company's international swine expertise can be applied to local conditions and diseases in China.

This new company Ceva EBVAC will benefit from the extensive scientific networks already established by its two partners, who have both agreed to invest significantly in a new research and development programme.

In addition, EBVAC has recently made significant investment to build a world class, industrial facility that will permit this new dynamic in R&D to be converted into vaccines of the highest quality.

Finally, combining the two salesforces and training them to roll out Ceva's innovative swine management programmes - Lung programme and Respinomics will allow the company to reach many more swine producers and encourage them to adopt the “new-style professional farming methods” recommended by Government in its latest five year plan.

Dr Marc Prikazsky, Chairman and Managing Director of Ceva commented: “I am delighted that EBVAC and their shareholders have accepted our offer to create this exciting, new partnership. China is a country that no global animal health company can ignore. Given that half of the world’s pigs are raised here and demand for pork products is set to rise even further, if you are not present in this market, you simply cannot be considered a global swine company."

© 2000 - 2023 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.